How much does IBRANCE (Palbociclib Capsules) Cost& price without insurance in China?
IBRANCE® is the commercial brand name of Palbociclib Capsules, a first-in-class, orally active cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by Pfizer. It exerts anti-tumor activity by selectively inhibiting CDK4/6, thereby blocking the phosphorylation of the retinoblastoma (Rb) protein, arresting the cell cycle at the G1 phase, and suppressing the proliferation of hormone receptor-positive breast cancer cells.
Main Indications
In combination with an aromatase inhibitor, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy;
In combination with fulvestrant, for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease progression following endocrine therapy.
Common Side Effects
Common adverse reactions: Neutropenia, leukopenia, fatigue, anemia, upper respiratory tract infection, nausea, stomatitis, alopecia, diarrhea, thrombocytopenia, decreased appetite, vomiting, asthenia, peripheral neuropathy, and epistaxis.
Laboratory abnormalities: Decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, and decreased platelet count.
Severe but manageable risks: Severe neutropenia with fever or infection, interstitial lung disease/pneumonitis, and venous thromboembolism.
Approval Status in China
IBRANCE® (Palbociclib Capsules, 125mg) was officially approved for marketing in China in July 2018. It is currently a prescription drug included in China’s Category B medical insurance.
Buy IBRANCE (Palbociclib Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
